FDA
-
-
-
-
-
-
-
Wedbush Upgrades Abivax (ABVX) to Neutral
-
-
-
-
-
-
-
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely
-
-
-
-
-
-
-
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
-
-
-
-
-
-
-
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
-
-
-
-
-
-
-
Abivax Announces a Change to the Composition of its Board of Directors
-
-
-
-
-
-
-
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

